GEMPHIRE THERAPEUTICS INC. (NASDAQ:GEMP) Files An 8-K Other Events

Item 8.01 Other Events.

On June 28, 2017, Gemphire Therapeutics Inc. issued a press
release announcing top-line data on the LDL-C primary endpoint
from its COBALT-1 Phase 2b clinical trial of gemcabene in
homozygous familial hypercholesterolemia (HoFH) patients.

A copy of the press release is filed as Exhibit99.1 to this
Current Report on Form8-K and incorporated herein by
reference.Information contained on or accessible through any
website reference in the press release is not part of, or
incorporated by reference in, this Current Report on Form 8-K,
and the inclusion of such website addresses in this Current
Report on Form 8-K by incorporation by reference of the press
release is as inactive textual references only.

Gemphire Therapeutics Inc. Exhibit
EX-99.1 2 ex-99d1.htm EX-99.1 Gemp_8-K_Ex_99.1 Exhibit 99.1     Gemphire Announces Top-Line Data from COBALT-1 Phase 2b Clinical Trial in HoFH Patients   Gemcabene achieves primary endpoint for LDL cholesterol in phase 2b HoFH trial   Company to host conference call at 4:30 pm ET today     LIVONIA,…
To view the full exhibit click here
About GEMPHIRE THERAPEUTICS INC. (NASDAQ:GEMP)

Gemphire Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in the development and commercialization of therapeutics to treat cardiovascular and metabolic diseases. It is developing its product candidate, gemcabene (CI-1027), which is a once-daily, oral therapy for patients who are unable to achieve normal levels of low-density lipoprotein cholesterol (LDL-C) or triglycerides with approved therapies, primarily statin therapy. Gemcabene is liver-directed and inhibits apolipoprotein C-III (apoC-III) protein in the liver and may inhibit acetyl-CoA carboxylase (ACC) in the liver. Gemcabene blocks the overall production of hepatic triglycerides and cholesterol. Gemcabene has been tested as monotherapy and in combination with statins and other drugs in over 895 subjects, across approximately 18 Phase I and Phase II clinical trials. Gemcabene is used as an adjunctive therapy to reduce LDL-C, high-sensitivity C-reactive protein (hsCRP) and triglycerides.